Company / CapEx per Share
Fulcrum Therapeutics, Inc. CapEx per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$4.96
FY2025
5-year range
$4.49 / $48.44
FY2021-FY2025
Trend
+10.5%
vs FY2024
Sector context
#5 of 192
Health Care
What the data says
Among 192 Health Care companies, Fulcrum Therapeutics, Inc. is in the top 3% for capex per share. CapEx per Share returned to growth in FY2025 after 6 years of decline, reaching $4.96.
Based on SEC 10-K filings.
4.96 in FY2025 with a 5-year CAGR of -37.7%. Top quartile in the Health Care sector.
Declined from $8.29 to $4.96 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -51.6%
- 5-Year CAGR
- -37.7%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 192This company $4.96 Sector average $3.54
▼
+40.1% above sector average
Key checks
Key Insights
- In FY2025, capex per share increased 10.5% year-over-year.
- Ranks #5 out of 192 companies in the Health Care sector.
- Peak capex per share was recorded in FY2018.
- Lowest capex per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.96 | +10.5% |
| FY2024 | $4.49 | -45.9% |
| FY2023 | $8.29 | -81.0% |
| FY2022 | $43.63 | -9.9% |
| FY2021 | $48.44 | -8.5% |
| FY2020 | $52.93 | -31.5% |
| FY2019 | $77.22 | -98.9% |
| FY2018 | $7144.79 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026